
PRODUCT CLASSIFICATION
产品分类TECHNICAL ARTICLES
相关文章产品展示/ Product display
您的位置:首页 / 产品展示 / / CAR T-Cell Therapy Cell Lines / 79853Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ)

●Purchase●DescriptionAnti-CD19CAR/NFAT(Luciferase)ReporterJurkatCellLine(CD19SCFV-CD28-4-1BB-CD3ζ)isastablecelllineexpressingananti-CD19CARandanNFAT-dependentluciferasereporter
产品型号:79853
厂商性质:生产厂家
更新时间:2023-11-11
访 问 量:471
立即咨询
联系电话:
Anti-CD19 CAR/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ) is a stable cell line expressing an anti-CD19 CAR and an NFAT-dependent luciferase reporter. The reporter cell line has been validated for anti- CD19 expression by flow cytometry, and for luciferase reporter activation by target cells, including the CD19 CHO cell line. Anti-CD19 CAR consists of the anti-CD19 scFv linked to 3rd generation CAR containing the CD28, 4-1BB co-stimulatory domains and the CD3ζ signaling domain.
The cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing is performed in primary T cells.

Figure 1: Lenti-vector used to generate anti-CD19 CAR lentivirus.

Figure 2. Schematic of anti-CD19 CAR.
Anti-CD19 (scFv) is linked to the 3rd generation CAR with CD28 transmembrane and costimulatory domains, 4-1BB, and CD3ζ components.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.